ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Short Interest Up 44.9% in August

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) was the recipient of a large growth in short interest in August. As of August 31st, there was short interest totalling 2,420,000 shares, a growth of 44.9% from the August 15th total of 1,670,000 shares. Based on an average daily volume of 299,400 shares, the short-interest ratio is currently 8.1 days.

Insiders Place Their Bets

In other ANI Pharmaceuticals news, COO Muthusamy Shanmugam sold 11,000 shares of the business’s stock in a transaction that occurred on Monday, July 15th. The stock was sold at an average price of $63.38, for a total transaction of $697,180.00. Following the completion of the sale, the chief operating officer now directly owns 671,620 shares of the company’s stock, valued at approximately $42,567,275.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other ANI Pharmaceuticals news, SVP Chad Gassert sold 20,000 shares of the business’s stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $63.44, for a total transaction of $1,268,800.00. Following the completion of the sale, the senior vice president now directly owns 193,226 shares of the company’s stock, valued at approximately $12,258,257.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Muthusamy Shanmugam sold 11,000 shares of the business’s stock in a transaction that occurred on Monday, July 15th. The stock was sold at an average price of $63.38, for a total value of $697,180.00. Following the completion of the transaction, the chief operating officer now owns 671,620 shares in the company, valued at approximately $42,567,275.60. The disclosure for this sale can be found here. In the last ninety days, insiders sold 65,757 shares of company stock valued at $4,075,585. Corporate insiders own 12.70% of the company’s stock.

Hedge Funds Weigh In On ANI Pharmaceuticals

Institutional investors have recently bought and sold shares of the company. Innealta Capital LLC purchased a new position in ANI Pharmaceuticals in the second quarter valued at approximately $65,000. Ridgewood Investments LLC purchased a new stake in shares of ANI Pharmaceuticals during the second quarter worth $85,000. SG Americas Securities LLC purchased a new stake in shares of ANI Pharmaceuticals during the first quarter worth $106,000. ADAR1 Capital Management LLC purchased a new stake in shares of ANI Pharmaceuticals during the fourth quarter worth $132,000. Finally, Clear Street Markets LLC purchased a new stake in shares of ANI Pharmaceuticals during the fourth quarter worth $140,000. Hedge funds and other institutional investors own 76.05% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the company. StockNews.com downgraded ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, September 7th. Truist Financial restated a “hold” rating and issued a $60.00 target price (down previously from $80.00) on shares of ANI Pharmaceuticals in a research note on Wednesday, September 11th. Finally, HC Wainwright restated a “buy” rating and issued a $94.00 target price on shares of ANI Pharmaceuticals in a research note on Wednesday, August 7th. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $77.75.

ANI Pharmaceuticals Price Performance

ANI Pharmaceuticals stock opened at $58.51 on Monday. ANI Pharmaceuticals has a 12 month low of $48.20 and a 12 month high of $70.81. The company has a current ratio of 3.97, a quick ratio of 3.07 and a debt-to-equity ratio of 0.62. The business’s 50 day simple moving average is $61.39 and its 200 day simple moving average is $63.93. The company has a market cap of $1.23 billion, a price-to-earnings ratio of 36.57 and a beta of 0.71.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings data on Tuesday, August 6th. The specialty pharmaceutical company reported $1.02 EPS for the quarter, beating the consensus estimate of $0.95 by $0.07. ANI Pharmaceuticals had a return on equity of 15.64% and a net margin of 5.01%. The business had revenue of $138.00 million for the quarter, compared to the consensus estimate of $129.09 million. During the same quarter in the prior year, the business earned $1.06 earnings per share. ANI Pharmaceuticals’s revenue for the quarter was up 18.5% on a year-over-year basis. Sell-side analysts forecast that ANI Pharmaceuticals will post 3.5 EPS for the current year.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.